The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1319
August 24, 2009
View Complete Issue         Table of Contents 2019 
Insulin Glargine (Lantus) and Cancer Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin Glargine (Lantus) and Cancer Risk
August 24, 2009 (Issue: 1319)
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Glargine (Lantus) and Cancer Risk
Article code: 1319c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.